Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical company MSD (tradename of Merck & Co., Inc., Rahway, N.J., U.S.).
Continue Reading this article here
